Have Questions? Email support@soracilabs.com
GLP-1, GIP and Glucagon: How Single, Dual and Triple Agonists Differ
Incretin research in three generations — single-receptor GLP-1 agonists, dual GIP/GLP-1 agonists like tirzepatide, and triple GIP/GLP-1/glucagon agonists like retatrutide.
In short
Incretin research has moved through three generations in under a decade: single-receptor GLP-1 agonists, then dual GIP/GLP-1 agonists such as tirzepatide, and now triple GIP/GLP-1/glucagon agonists such as retatrutide. Each step adds a receptor, and each added receptor changes the metabolic picture in ways the literature is still characterising.
What incretins actually are
A triple agonist peptide engages three receptors at once, and that is where the current generation of incretin work sits. Incretins are gut-derived hormones released after eating that amplify insulin secretion from pancreatic beta cells. The two principal human incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Together they account for a substantial share of the insulin response to an oral glucose load — considerably more than the same glucose given intravenously, a difference known as the incretin effect.
Both hormones act through class B G-protein-coupled receptors, and both native forms are degraded within minutes by dipeptidyl peptidase-4. The entire field has therefore been built on engineered analogs with extended half-lives rather than on the native sequences.
Three generations, up to the triple agonist peptide
| Generation | Reference compound | Receptors targeted | Distinguishing feature |
|---|---|---|---|
| Single agonist | Semaglutide | GLP-1 | Established the category — glucose-dependent insulin release, slowed gastric emptying |
| Dual agonist | Tirzepatide | GIP + GLP-1 | Adds GIP receptor activity alongside GLP-1 |
| Triple agonist | Retatrutide | GIP + GLP-1 + glucagon | Adds glucagon receptor agonism, associated in the literature with increased energy expenditure |
Why adding the glucagon receptor is the interesting part
Glucagon is normally framed as insulin’s counter-regulatory partner: it raises blood glucose. Deliberately agonising its receptor in a metabolic compound therefore looks counter-intuitive. The rationale in the literature is that glucagon receptor activation increases hepatic energy expenditure, and that pairing it with sufficient GLP-1 and GIP activity offsets the glycaemic consequence while retaining the expenditure effect.
That balancing act is the central pharmacological question in triple-agonist research, and it is the reason retatrutide is studied as a single engineered molecule rather than as a combination of separate compounds.
What the published data show
Retatrutide’s phase 2 obesity trial was published in the New England Journal of Medicine in 2023 and is the reference point most subsequent literature works from.1 Tirzepatide’s dual-agonist profile was characterised across the SURPASS and SURMOUNT clinical programmes.2
An important distinction
The published trials describe pharmaceutical-grade compounds studied under clinical protocols. Research materials supplied for laboratory use are not those approved products, are not manufactured to pharmaceutical specification, and are not intended for administration to humans or animals. The literature is cited here to explain the pharmacology that laboratory work references.
Triple agonist peptide receptor pharmacology at a glance
| Receptor | Native ligand | Primary tissues | Effect most cited in the literature |
|---|---|---|---|
| GLP-1R | GLP-1 | Pancreatic islets, brain, GI tract | Glucose-dependent insulin secretion; slowed gastric emptying; satiety signalling |
| GIPR | GIP | Pancreatic islets, adipose tissue, brain | Insulinotropic activity; adipose and central effects still under active study |
| GCGR | Glucagon | Liver, adipose tissue | Hepatic glucose output; increased energy expenditure |
A useful way to read the table: GLP-1 and GIP receptor activity sit largely on the intake and insulin-secretion side, while glucagon receptor activity sits on the expenditure side. A triple agonist engages both sides of the energy balance equation within one molecule, which is exactly why it is studied separately from dual agonists rather than as a minor variant of them.
Triple agonist peptide: practical notes for laboratory handling
Incretin analogs are peptides and follow the same handling rules as any other lyophilized research peptide. A few points recur specifically with this class:
- They are supplied lyophilized and should be equilibrated to room temperature before the vial is opened.
- They are water-soluble and reconstitute cleanly in bacteriostatic water — see the reconstitution guide for the full procedure.
- Solutions are considerably less stable than the dry powder; aliquot before freezing rather than repeatedly thawing a single stock.
- Concentrations in this class are frequently worked in milligrams per millilitre, so record the reconstitution volume on the vial at the time you prepare it.
Incretin research materials
GLP-3RTfrom $49.99
Tirzepatidefrom $59.99
All materials supplied for laboratory research use only.
Triple agonist peptide: frequently asked questions
What is the difference between a dual and a triple agonist?
The number of receptors the single molecule activates. A dual agonist such as tirzepatide engages the GIP and GLP-1 receptors; a triple agonist such as retatrutide adds the glucagon receptor. It is one molecule with multiple receptor affinities, not a blend of separate compounds.
Is retatrutide the same thing as GLP-3?
“GLP-3” is a common informal name in the research-material market for retatrutide-based material. It is not an official pharmacological designation — there is no endogenous hormone called GLP-3.
Why does adding glucagon receptor activity not raise blood glucose?
In the published clinical work the GLP-1 and GIP components are understood to offset the glycaemic effect of glucagon receptor agonism while the energy-expenditure effect is retained. Characterising that balance is a major focus of the research.
Are these compounds the same as the approved medicines?
No. Research materials supplied for laboratory use are not pharmaceutical products, are not manufactured to pharmaceutical specification, and are not approved for human or veterinary use.
How should incretin analogs be stored?
Lyophilized and frozen for long-term storage; reconstituted solutions are far less stable and should be aliquoted and kept frozen, with realistic expectations measured in weeks rather than months.
The incretin axis is not the only endocrine system these compounds are grouped with. For the growth-hormone side, see tesamorelin and ipamorelin, which reach one cell through two separate receptors.
References
1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. PubMed 37366315
2. Eli Lilly and Company. SURPASS and SURMOUNT clinical trial programmes for tirzepatide. ClinicalTrials.gov
3. Bachem. Handling and Storage Guidelines for Peptides. bachem.com
Research use only. The materials discussed here are supplied by Soraci Labs exclusively for laboratory research and analytical applications. They are not approved by the FDA for human or veterinary use, are not medications, dietary supplements, cosmetics or food products, and must not be consumed or administered. Nothing here is medical advice.